Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent

Prostate

Volumn 73, Issue 6, 2013, Pages 668-676

  Taioli, Emanuela ^a   Sears, Vestra ^b   Watson, Alexis ^c   Flores Obando, Rafael E ^d   Jackson, Maria D ^e   Ukoli, Flora A ^f   De Syllos Cõlus, Ilce M ^g   Fernandez, Pedro ^h   McFarlane Anderson, Norma ^e   Ostrander, Elaine A ⁱ   Rodrigues, Iara S ^g   Stanford, Janet L ^j   Taylor, Jack A ^k   Tulloch Reid, Marshall ^e   Ragin, Camille C R ^l  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b PHILANDER SMITH COLLEGE   (United States)

^c HOWARD UNIVERSITY   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e UNIVERSITY OF THE WEST INDIES   (Jamaica)

^f MEHARRY MEDICAL COLLEGE   (United States)

^g STATE UNIVERSITY OF LONDRINA   (Brazil)

^h STELLENBOSCH UNIVERSITY   (South Africa)

ⁱ NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^j USA   (United States)

^k NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^l FOX CHASE CANCER CENTER   (United States)

more..

Author keywords

African ancestry; genetics; prostate cancer

Indexed keywords

CYTOCHROME P450 17; CYTOCHROME P450 3A4; PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; ARTICLE; CANCER PATIENT; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION;

ADULT; AFRICAN AMERICANS; AGED; CARIBBEAN REGION; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP3A; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NIGERIA; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS; SEER PROGRAM; STEROID 17-ALPHA-HYDROXYLASE; UNITED STATES;

EID: 84875760778     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22612     Document Type: Article

References (41)

1. Kheirandish P, Chinegwundoh F,. Ethnic differences in prostate cancer. Br J Cancer 2011; 105: 481-485.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer Statistics Review, 1975-2009. Bethesda, MD, based on November 2011 SEER data submission, posted to the SEER web site, April 2012: National Cancer Institute, 2011.
3. Leitzmann MF, Rohrmann S,. Risk factors for the onset of prostatic cancer: Age, location, and behavioral correlates. Clin Epidemiol 2012; 4: 1-11.
4. Chornokur G, Dalton K, Borysova ME, Kumar NB,. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 2011; 71: 985-997.
5. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP,. Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988; 263: 424-436.
6. Waterman MR, Keeney DS,. Genes involved in androgen biosynthesis and the male phenotype. Horm Res 1992; 38: 217-221.
7. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R,. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3: 1873-1876.
8. Wang F, Zou YF, Feng XL, Su H, Huang F,. CYP17 gene polymorphisms and prostate cancer risk: A meta-analysis based on 38 independent studies. Prostate 2011; 71: 1167-1177.
9. Ragin CC, Taioli E, McFarlane-Anderson N, Avery G, Bennett F, Bovell-Benjamin A, Brown TA, Carrington A, Campbell-Everett L, Ford J, Hennis A, Jackson M, Lake S, Leske MC, Magai C, Nemesure B, Neugut A, Odedina F, Okobia M, Patrick A, Best PW, Reams RR, Roberts R, Scott-Hastings S, Sharma S, Wheeler V, Wu SY, Bunker C,. African-Caribbean cancer consortium for the study of viral, genetic and environmental cancer risk factors. Infect Agent Cancer 2007; 2: 17-22.
10. Taioli E,. International collaborative study on genetic susceptibility to environmental carcinogens. Cancer Epidemiol Biomarkers Prev 1999; 8: 727-728.
11. Ukoli F, Osime U, Akereyeni F, Okunzuwa O, Kittles R, Adams-Campbell L,. Prevalence of elevated serum prostate-specific antigen in rural Nigeria. Int J Urol 2003; 10: 315-322.
12. Rodrigues IS, Kuasne H, Losi-Guembarovski R, Fuganti PE, Gregorio EP, Kishima MO, Ito K, Freitas Rodrigues MA, de Syllos Colus IM,. Evaluation of the influence of polymorphic variants CYP1A1 2B, CYP1B1 2, CYP3A4 1B, GSTM1 0, and GSTT1 0 in prostate cancer. Urol Oncol 2011; 29: 654-663.
13. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL,. Statin use and risk of prostate cancer: Results from a population-based epidemiologic study. Am J Epidemiol 2008; 168: 250-260.
14. Bangsi D, Zhou J, Sun Y, Patel NP, Darga LL, Heilbrun LK, Powell IJ, Severson RK, Everson RB,. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol 2006; 24: 21-27.
15. Berndt SI, Chatterjee N, Huang WY, Chanock SJ, Welch R, Crawford ED, Hayes RB,. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 165-168.
16. Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, Thompson IM, Leach RJ,. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 1869-1880.
17. dos Santos RM, de Jesus CM, Trindade Filho JC, Trindade JC, de Camargo JL, Rainho CA, Rogatto SR,. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy. DNA Cell Biol 2008; 27: 497-503.
18. Fernandez P, de Beer PM, van der ML, Heyns CF,. Genetic variations in androgen metabolism genes and associations with prostate cancer in South African men. S Afr Med J 2010; 100: 741-745.
19. Kittles RA, Panguluri RK, Chen W, Massac A, Ahaghotu C, Jackson A, Ukoli F, Adams-Campbell L, Isaacs W, Dunston GM,. Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 2001; 10: 943-947.
20. Kittles RA, Chen W, Panguluri RK, Ahaghotu C, Jackson A, Adebamowo CA, Griffin R, Williams T, Ukoli F, Adams-Campbell L, Kwagyan J, Isaacs W, Freeman V, Dunston GM,. CYP3A4-V and prostate cancer in African Americans: Causal or confounding association because of population stratification? Hum Genet 2002; 110: 553-560.
21. Kwon EM, Holt SK, Fu R, Kolb S, Williams G, Stanford JL, Ostrander EA,. Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk. Cancer Epidemiol Biomarker Prev 2010; 36 (4): 347-353.
22. Lunn RM, Bell DA, Mohler JL, Taylor JA,. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999; 20: 1727-1731.
23. Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprini D, Chu W, Ho M, Sweet J, Evans A, Toi A, Pollak M, Narod SA,. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 1429-1437.
24. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS,. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999; 8: 901-905.
25. Sarma AV, Dunn RL, Lange LA, Ray A, Wang Y, Lange EM, Cooney KA,. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: The Flint Men's Health Study. Prostate 2008; 68: 296-305.
26. Stanford JL, Noonan EA, Iwasaki L, Kolb S, Chadwick RB, Feng Z, Ostrander EA,. A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 243-247.
27. Zeigler-Johnson C, Friebel T, Walker AH, Wang Y, Spangler E, Panossian S, Patacsil M, Aplenc R, Wein AJ, Malkowicz SB, Rebbeck TR,. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res 2004; 64: 8461-8467.
28. Sutton AJ,. Methods for meta-analysis in medical research. Chichester, West Sussex, UK: John Wiley; 2000.
29. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
30. Egger M, Davey SG, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
31. Ntais C, Polycarpou A, Ioannidis JPA,. Association of the CYP17 gene polymorphism with the risk of prostate cancer: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12: 120-126.
32. Ragin C, Langevin S, Rubin S, Taioli E,. Review of studies on metabolic genes and cancer in populations of African descent. Genet Med 2010; 12: 12-18.
33. Picado-Leonard J, Miller WL,. Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA 1987; 6: 439-448.
34. Salonia A, Gallina A, Briganti A, Suardi N, Capitanio U, Abdollah F, Bertini R, Freschi M, Rigatti P, Montorsi F,. Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. Cancer 2011; 117: 5029-5038.
35. Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK,. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology 2009; 73: 356-361.
36. Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, Heyden NL, Vaughan ED Jr., PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology 2009; 73: 935-939.
37. Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lippman SM, Coltman CA,. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol 2007; 178: 107-109.
38. Thompson IM, Pauler AD, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr., Prediction of prostate cancer for patients receiving finasteride: Results from the prostate cancer prevention trial. J Clin Oncol 2007; 25: 3076-3081.
39. Ukoli FA, Fowke JH, Akumabor P, Oguike T, Taher KA, Murff HJ, Amaefuna ER, Kittles R, Ahaghotu C, Osime U, Beech DJ,. The association of plasma fatty acids with prostate cancer risk in African Americans and Africans. J Health Care Poor Underserved 2010; 21: 127-147.
40. Aiken WD,. Historical determinants of contemporary attributes of African descendants in the Americas: The androgen receptor holds the key. Med Hypotheses 2011; 77: 1121-1124.
41. Keshava C, McCanlies EC, Weston A,. CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: A HuGE review. Am J Epidemiol 2004; 160: 825-841.